#USA #Orlando #Rutgers Cancer Institute #Blood Cancer #ASH 2025

Insights into Blood Cancer Research at the ASH Annual Meeting

From December 6 to 9, 2025, the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH) will take place in Orlando, Florida, showcasing vital advancements in the field of hematology. Among the major contributors to this year's exposition are the physician-scientists from the Rutgers Cancer Institute and RWJBarnabas Health, premier institutions leading the charge in blood cancer research.

With a total of 93 peer-reviewed abstracts accepted, the contributions include 32 oral presentations, 60 poster presentations, and a satellite symposium, reflecting the pressing need for advancements in treatments for conditions such as Hodgkin lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. This impressive representation highlights the commitment these institutions have made toward innovation in cancer care and research.

Key Research Highlights

The research to be presented showcases a range of important insights, including but not limited to:

• - A comparative study evaluating therapies for advanced-stage classical Hodgkin lymphoma. This study revealed that PET-adaptive escBEACOPP therapy outperformed traditional ABVD therapy in terms of progression-free survival.
• - An analysis of the Advanced Hodgkin Lymphoma International Prognostic Index (A-HIPI) showed its superior predictive capabilities for treatment responses, confirming its utility regardless of the therapeutic regimen applied.
• - A real-world study examining the safety and efficacy of peripheral intravenous catheters versus central venous catheters for chemotherapy in lymphoma patients. This research indicated that while both access types had low complication rates, peripheral access might be more beneficial in particular circumstances.
• - Findings related to the racial and ethnic disparities in access to novel treatments for chronic lymphocytic leukemia, revealing alarming trends that underscore the importance of addressing social determinants of health in healthcare access.

Commitment to Transformative Research and Care

Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at the Rutgers Cancer Institute, emphasized the importance of the ASH Annual Meeting for showcasing transformative breakthroughs in blood disease research. He noted that the presentations highlight the institution's dedication to making impactful strides in patient care.
Furthermore, the integration of the Jack Sheryl Morris Cancer Center, New Jersey's first dedicated cancer hospital, enhances the synergy between research and clinical application, allowing for the translation of findings into real-world patient care. This connectivity aims to foster groundbreaking advancements that not only influence local patient outcomes but also set the benchmark for national standards in cancer treatment.

Looking Ahead

As the ASH Annual Meeting approaches, the expectations around innovative studies from the Rutgers Cancer Institute and RWJBarnabas Health continue to build. Their research embodies the future of blood cancer management and reflects a broader movement within the medical community to prioritize precision medicine and equitable access to healthcare.
By leveraging both sophisticated research methodologies and a patient-centered approach to care, these institutions are poised to lead the change necessary for better outcomes in blood cancer treatment. For those interested in the latest in hematology research, the findings presented at ASH 2025 will prove to be an essential point of reference.

For more information on these presentations and the ongoing work at Rutgers Cancer Institute and RWJBarnabas Health, visit their respective websites or follow their updates during the ASH conference.